banner
Platforms

Platforms

Introduction

Driving Progress Through Technology: CD BioGlyco’s Platforms Lead the Way

CD BioGlyco is a pioneering biotechnology firm that has engineered and refined an array of research platforms focused on glycobiology. Glycobiology is defined as the study of the structure, biosynthesis, and biological functions of glycans and saccharide conjugates (including glycoproteins, glycolipids, proteoglycans, etc.), as well as protein-glycan interactions. Glycogenomics, glycoproteomics, glycomics, and geoinformatics help us better understand the various cellular events involved in saccharides and the role of glycans in diseases. In the production of biological agents, glycans also affect the therapeutic properties of protein drugs and their immune responses.

Fig.1 Carbohydrate generation and glycan microarray.Fig.1 Influence of glycans and glycan-binding proteins in death receptor signaling and function. (Zol-Hanlon & Schumann, 2020)

To facilitate clients in exploring the multifaceted dimensions of glycobiology research, CD BioGlyco endeavors to provide extensive platforms. These diverse platforms have made available an array of sophisticated analytical methodologies and data analysis techniques tailored for glycobiological investigations. Our goal is to offer a wide range of services, enabling clients to explore the intricate world of glycobiology with thoroughness and precision. Our first-class technology platforms and experienced scientists provide clients with high-precision, high-efficiency, and high-throughput services.

What We Can Offer

Platforms at CD BioGlyco

At CD BioGlyco, we also have a range of ready-made Products for selection. These products greatly assist clients in their various glycobiology research. Our products are distinguished by their outstanding quality, supported by strong guarantees, and are adaptable to fulfill the requirements of multiple industries. Our products encompass, but are not limited to:

On the whole, CD BioGlyco has provided a large number of advanced analysis techniques and data analysis tools for glycobiology research. Glyco™ synthesis platform helps to synthesize a variety of glycoconjugates. Glycomics results are combined with other "omics data sets" to gain a deeper understanding and insight into the nature of glycosylation in complex cellular processes. Through our glycoproteomics platform, we identify, classify, quantify, and characterize glycoproteins. The glycobiology microarray platform is widely used to analyze the entire glycogen group and glycosylase under pathological conditions. Glyco™ vaccine development helps accelerate vaccine development and preclinical research. The glycoengineering platform is an important strategy for improving the safety, consistency, and reduced immunogenicity of biological drugs.

Publication

Publication Data

Technology: Solid-phase synthesis, Chemical-enzymatic synthesis, Catch and release strategy, Glycan microarray

Journal: Frontiers in Chemistry

IF: 5.5

Published: 2020

Results: This scholarly review delves into recent strides in chemo-enzymatic methodologies aimed at fabricating precisely structured N-glycans, pivotal for comprehending protein functionalities and fostering innovative therapeutic avenues. The authors describe advancements in substrate formulation, glycosyltransferase characterization, and the synthesis of high-mannose, hybrid, and complex N-glycan varieties, underscoring the synergistic benefits of amalgamating chemical and enzymatic approaches to realize efficient and precise N-glycan synthesis. It also probes emergent prospects such as automated synthesis technologies, underscoring their potential applications in refining glycoprotein formulation and advancing biomarker delineation. Ultimately, the authors describe these methodologies’ potential to catalyze paradigm shifts in N-glycan exploration and therapeutic interventions.

Fig.2 Enzymes for making high-mannose, hybrid, and complex N-glycans.Fig.2 Typical glycosyltransferases and glycosidases for the enzymatic synthesis of high-mannose, hybrid, and complex-type N-glycans. (Chao, et al., 2020)

Applications

Applications

  • Glyco™ synthesis platform can be used to synthesize complex carbohydrate molecules for use in glycobiology, materials science, drug development, and other fields.
  • Glycomics platform is applied to analyze structures and functions of complex carbohydrates in therapeutic and diagnostic research of cancer, infectious diseases, and metabolic disorders.
  • Glycoproteomics platform will be utilized to identify, quantify, and characterize glycoproteins from biological samples to support the development of new therapies.
  • Glycosylation site-specific ADC development platform can be employed for research and development of targeted and effective anti-cancer drugs.
  • Carbohydrate-based glycomedicine development platform is useful for discovering and developing carbohydrate-based therapeutic drugs for the inhibition of inflammatory and autoimmune diseases, cancer, and viral infections.
  • Through our platform for the production of ingredients, we help clients to improve nutritional and functional characteristics.
  • Our MOPCGM can be used to identify and analyze metabolic abnormalities in cancer cells to support the new therapeutic development.
  • The glycoengineering platform is used to modify proteins, cells, and tissues for the research of enhancing therapeutic efficacy and reducing immunogenicity.
  • The glycobiology microarray platform can be used for high-throughput analysis of glycan-protein interactions for the development of new therapies and diagnostic tools.
  • Glyco™ vaccine development platform can be employed to discover and develop carbohydrate-based vaccines for the prevention of infectious diseases and cancer.
  • Glycogenomics platform is useful to identify and characterize genes involved in glycogen metabolism for the development of new therapies for glycogen storage diseases.
Advantages

Advantages

  • CD BioGlyco's diverse glyco-biotechnology platforms support advancements in life sciences, pharmaceutical research, and vaccine development with innovative solutions.
  • CD BioGlyco possesses efficient and user-friendly glyco-analysis techniques to reduce experimental time and improve research efficiency and accuracy.
  • CD BioGlyco has extensive capabilities in glycan synthesis and modification for producing high-quality glycan that has various applications in drug discovery, biological research, and other industries.
  • CD BioGlyco supports large-scale data analysis and storage, facilitating ongoing scientific research and development.
  • CD BioGlyco has strong interdisciplinary expertise and collaborations, promoting the cross-pollination of ideas and solutions in glyco-related research areas.
  • CD BioGlyco is committed to innovation and continuous improvement and stays up-to-date with the latest technological advancements to meet the evolving needs of clients and the scientific community.
FAQs

Frequently Asked Questions

CD BioGlyco is a global biotechnology company that has accomplished several successful glycobiology projects. Firmly anchored in a steadfast commitment to excellence, CD BioGlyco combines profound expertise with state-of-the-art platforms, fostering unparalleled confidence in its capacity to meet the most exacting demands. Spanning a spectrum of integrated glyco-biotechnology platforms, its cadre of researchers is perpetually pioneers within life sciences, pharmaceuticals, and allied sectors. Esteemed for delivering premium solutions, we have become a good partnership grounded in trust and reliability. CD BioGlyco continues to drive advancements in glyco-related studies, playing a pivotal role in unlocking discoveries and understanding complex biological processes. Our technology platforms are constantly updated to meet the latest needs of our global clients. Our only goal is to provide high-quality services while saving time and effort for clients. If you are interested in our services, please contact us for more detailed information.

References

  1. Zol-Hanlon, M.I.; Schumann, B. Open questions in chemical glycobiology. Communications chemistry. 2020, 3(1): 102. (Open Access)
  2. Chao, Q.; et al. Recent progress in chemo-enzymatic methods for the synthesis of N-glycans. Frontiers in Chemistry. 2020, 8: 513. (Open Access)
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0